WE45491
Recruiting
For participation in this epidemiological(branch of medicine which deals with the incidence, distribution and control of diseases) study, a single-day visit at the study site is required. Participants will be recruited from HD clinics, and they will be asked to answer questions regarding their demographics, including sex, age, race and ethnicity, and their medical and medication history. At the end of the visit, a blood sample will be drawn to allow testing for a single nucleotide polymorphisms (SNPs) on the wild-type Huntington (wtHTT) and mutant Huntington (mHTT) alleles.
SNPs pronounced ‘snips’, are a single-letter spelling difference in a gene. They are common and most don’t change the function of the gene.
We have talked of SNPs before. WAVE Life Sciences was the first company to use this technique in HD trials: Precision 1 and 2 and Select.
Ages Eligible
for Study:
Sexes Eligible
for Study:
All
Accepts Healthy Volunteers:
No
- Have signed the Informed Consent Form (ICF)
- Aged 25 to 60 years, inclusive, at the time of signing the ICF
- Confirmation of Huntington Disease (HD) gene expansion mutation carrier status
- Confirmation of Total Functional Capacity (TFC) ≥9 and Total Motor Score (TMS) >6 within 12 months prior to signing the ICF
- Ability to tolerate blood draws.
None.
LOCATIONS
COUNTRIES
GERMANY
TRIAL SITE: Universitätsklinikum Ulm
Address: Ulm, Germany
Email: global-roche-genentech-trials@gene.com
Recruiting
UK
TRIAL SITE: National Hospital For Neurology and Neurosurgery
Address: London, United Kingdom
Email: global-roche-genentech-trials@gene.com